Pharma BD Deal Intelligence
Cephalon's $202.7M cash takeover of Australia's Arana Therapeutics never delivered — lead candidate placulumab was discontinued by 2012 with no Arana asset reaching approval. Cephalon itself was acquired by Teva just two years after the deal closed, folding the unproven biologics platform in before it could prove standalone value.
Cephalon's $223M bet on Arana's biologics platform produced no approved drug — lead asset placulumab (ART621) was discontinued, and Cephalon itself was absorbed by Teva just two years after closing.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Cephalon to acquire Arana Therapeutics for A$1.40 cash per share (~A$318M / US$207M), a ~70% premium to the 90-day VWAP; Arana directors unanimously recommend…
Cephalon's filed takeover offer for Arana detailed cash consideration, conditional sweetener (additional AU$0.05/share at 90% acceptance), and the strategic…
Cephalon completed its AU$318M / ~$202.7M acquisition of Arana, gaining a domain-antibody anti-TNF (ART621) in Phase 2, plus a portfolio of inflammatory and…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
AU$318M / ~$202.7M cash takeover offer for Australian biotech (anti-TNF, antibody platform). Closed Aug 10, 2009. Source: SEC, GenEngNews.
Cephalon's $223M bet on Arana's biologics platform produced no approved drug — lead asset placulumab (ART621) was discontinued, and Cephalon itself was absorbed by Teva just two years after closing.
Assessment window: 15yr post-close.
Rheumatoid arthritis is a chronic autoimmune inflammatory joint disease driven in part by TNF-alpha signaling; plaque psoriasis is a related TNF/IL-23-driven inflammatory skin condition. Anti-TNF biologics (Humira, Enbrel, Remicade) became the standard of care after methotrexate failure, creating a multi-billion-dollar class but leaving room for differentiated formats (e.g., domain antibodies offering smaller size, alternative routes, or lower cost).
By early 2009, the anti-TNF class was dominated by Abbott's Humira (adalimumab), Amgen/Pfizer's Enbrel (etanercept), and J&J/Merck's Remicade (infliximab) — collectively a >$15B global market. Arana's ART621 was a domain-antibody (dAb) format anti-TNF, the first dAb to reach the clinic, in Phase 2 for rheumatoid arthritis and psoriasis. The platform's strategic value to Cephalon was twofold: (1) ART621 offered a potentially lower-cost, smaller-format anti-TNF entry into a saturated market; and (2) Arana held an anti-TNF antibody patent estate licensed to Abbott (Humira) and J&J (Remicade), generating royalty income that Cephalon expected to offset near-term development costs. The AU$318M (~$202.7M) offer represented a ~69-70% premium and gave Cephalon — historically a CNS/oncology specialty pharma — its first biologics platform, complementing earlier purchases like Salmedix and CIMA Labs. Arana also brought a RANKL inhibitor for bone metastases, a colorectal cancer antibody (with Kyowa Hakko Kirin), an anti-ganglioside SCLC/melanoma program, and an IL-12/23 program for psoriasis/Crohn's. Cephalon itself was acquired by Teva in 2011 for $6.8B, folding the Arana assets into Teva's biologics operations.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / Arana Therapeutics Limited (this deal) | 2009 | $203M | 22 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Cephalon Inc. / Cell Therapeutics, Inc. | 2005 | $70M | 74 |
| Cephalon Inc. / Anesta Corp. | 2001 | $444M | 65 |
| Cephalon Inc. / Anesta Corp. | 2000 | $444M | 64 |
← Browse all deals · How we score deals
More: 2009 deals · Cephalon Inc. deals